Attenuated Salmonella typhimurium invades and decreases tumor burden in neuroblastoma

被引:24
作者
Barnett, SJ [1 ]
Soto, LJ [1 ]
Sorenson, BS [1 ]
Nelson, BW [1 ]
Leonard, AS [1 ]
Saltzman, DA [1 ]
机构
[1] Univ Minnesota, Sch Med, Dept Surg, Pediat Surg Sect, Minneapolis, MN 55455 USA
关键词
Salmonella; cancer; neuroblastoma; treatment; animal studies;
D O I
10.1016/j.jpedsurg.2005.03.015
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Introduction: We have previously shown that Salmonella elicits an antitumor response against hepatic adenocarcinomatous metastases. In vitro studies have demonstrated both intracellular invasion and proliferation of Salmonella within cultured neuroblastoma cells. We sought to demonstrate in vivo invasion, proliferation, and a potential antitumor response. Methods: A murine model for retroperitoneal neuroblastoma was established with viable neuroblastoma cells. A green fluorescent protein (GFP-Clontech, Palo Alto, CA) gene was inserted into our attenuated Salmonella species via electroporation. Fourteen days after retroperitoneal injection, the Salmonella typhhnuriu1n-pGFP construct was administered and studied. In separate experiments, the antitumor effect against neuroblastoma was studied in controls, Salmonella lacking an interleukin 2 (IL-2) gene (Sal-NG), and Salmonella containing an IL-2 gene (Salmonella-pIL2). Results: Consistent with previous reports, 74% of mice injected were found to have recognizable tumors. Salmonella was present within tumor cells. Average tumor volumes for control, Sal-NG, and Salmonella-pIL2 mice were 2024.3, 749.5, and 332.4 mm(3), respectively (P < .0001). Tumor weights for control, Sal-NG, and Salmonella-pJL2 mice were 2.218, 0.880, and 0.377 g, respectively (P < .0001). Conclusions: Attenuated Salmonella species can now be tracked via fluorescent microscopy within tumor cells. Furthermore, an 84% reduction in tumor burden was observed in those animals gavage fed Salmonella with the IL-2 gene. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:993 / 998
页数:6
相关论文
共 34 条
[1]  
ANDERSON PM, 1992, J IMMUNOTHER, V12, P19
[2]   EFFECTS OF ROUTE AND FORMULATION ON CLINICAL PHARMACOKINETICS OF INTERLEUKIN-2 [J].
ANDERSON, PM ;
SORENSON, MA .
CLINICAL PHARMACOKINETICS, 1994, 27 (01) :19-31
[3]   CYTOKINES IN LIPOSOMES - PRELIMINARY STUDIES WITH IL-1, IL-2, IL-6, GM-CSF AND INTERFERON-GAMMA [J].
ANDERSON, PM ;
HANSON, DC ;
HASZ, DE ;
HALET, MR ;
BLAZAR, BR ;
OCHOA, AC .
CYTOKINE, 1994, 6 (01) :92-101
[4]   INTERLEUKIN-2 IN LIPOSOMES - INCREASED INTRAVENOUS POTENCY AND LESS PULMONARY TOXICITY IN THE RAT [J].
ANDERSON, PM ;
HASZ, D ;
DICKRELL, L ;
SENCER, S .
DRUG DEVELOPMENT RESEARCH, 1992, 27 (01) :15-31
[5]  
ANDERSON PM, 1990, CANCER RES, V50, P1853
[6]   Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma [J].
Bowman, LC ;
Grossmann, M ;
Rill, D ;
Brown, M ;
Zhong, WY ;
Alexander, B ;
Leimig, T ;
Coustan-Smith, E ;
Campana, D ;
Jenkins, J ;
Woods, D ;
Brenner, M .
HUMAN GENE THERAPY, 1998, 9 (09) :1303-1311
[7]  
BRODEUR GM, 1997, PRINCIPLES PRACTICE, P337
[8]  
CHEUNG IY, 2002, CANCER, V94, P3024
[9]  
CHEUNG IY, 2002, CANCER, V94, P302
[10]   SALMONELLA-TYPHIMURIUM DELETION MUTANTS LACKING ADENYLATE-CYCLASE AND CYCLIC-AMP RECEPTOR PROTEIN ARE AVIRULENT AND IMMUNOGENIC [J].
CURTISS, R ;
KELLY, SM .
INFECTION AND IMMUNITY, 1987, 55 (12) :3035-3043